Publications by authors named "Mayu Higuchi"

Claim this Profile
D
Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds.
Shohei Kimura, Nobuharu Tamaki, Mayu Higuchi, Takuya Shima, Mina Taguchi

J Clin Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older.
Kenta Takaura, Kaoru Tsuchiya, Mina Taguchi, Yuzuki Tokunaga, Naoki Uchihara, Mayu Higuchi

PLoS One· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial effects of epigallocatechin-3-gallate, a catechin abundant in green tea, on periodontal disease-associated bacteria.
Mayu Higuchi, Yuki Abiko, Jumpei Washio, Nobuhiro Takahashi

Arch Oral Biol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CRK14 gene encoding a cysteine-rich receptor-like kinase is implicated in the regulation of global proliferative arrest in Arabidopsis thaliana.
Sho Imai, Hikaru Hirozawa, Shingo Sugahara, Chisato Ishizaki, Mayu Higuchi

Genes Cells· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Keito Suzuki, Nobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, Yudai Yamazaki, Mayu Higuchi

Hepatol Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Keito Suzuki, Yutaka Yasui, Kaoru Tsuchiya, Hiroaki Matsumoto, Yudai Yamazaki, Mayu Higuchi

J Gastroenterol Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis.
Nobuharu Tamaki, Kenta Takaura, Mayu Higuchi, Yutaka Yasui, Jun Itakura

Diagnostics (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Michiko Yamada-Shimizu, Nobuharu Tamaki, Masayuki Kurosaki, Naoki Uchihara, Keito Suzuki, Mayu Higuchi

Intern Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B.
Nobuharu Tamaki, Mayu Higuchi, Taisei Keitoku, Yudai Yamazaki, Naoki Uchihara

JGH Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, Mayu Higuchi

Quant Imaging Med Surg· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Yuka Hayakawa, Nobuharu Tamaki, Hiroyuki Nakanishi, Masayuki Kurosaki, Yuki Tanaka, Mayu Higuchi

Intern Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
Taisei Keitoku, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Mayu Higuchi

J Viral Hepat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Mayu Higuchi

Hepatol Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Shuhei Sekiguchi, Kaoru Tsuchiya, Yutaka Yasui, Kento Inada, Sakura Kirino, Mayu Higuchi

Cancer Rep (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension.
Koji Yamashita, Masayuki Kurosaki, Hiroyuki Nakanishi, Yuki Tanaka, Shun Ishido, Mayu Higuchi

JGH Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
Kento Inada, Nobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, Koji Yamashita, Mayu Higuchi

J Gastroenterol Hepatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Hiroaki Matsumoto, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Hayakawa, Yutaka Yasui, Mayu Higuchi

Cancers (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
Shun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, Yutaka Yasui, Yuka Hayakawa, Mayu Higuchi

PLoS One· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.
Shun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, Yuki Tanaka, Kento Inada, Mayu Higuchi

JGH Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Mayu Higuchi

Invest New Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: predictive role of magnetic resonance elastography in chronic liver disease-still a long way to go. Authors' reply.
Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, Namiki Izumi

Aliment Pharmacol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: association of laboratory indexes and magnetic resonance elastography-associated liver stiffness with complications and mortality-authors' reply.
Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, Namiki Izumi

Aliment Pharmacol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
Kenta Takaura, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Kouji Yamashita, Mayu Higuchi

PLoS One· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.
Mayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Sakura Kirino

Aliment Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease.
Nobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, Namiki Izumi

Hepatol Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis